A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.

@article{Hong2014API,
  title={A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.},
  author={Yong Sang Hong and Sung Sook Lee and Kyu-pyo Kim and J S Lee and Yoon-koo Kang and Sang Joon Shin and Joong Bae Ahn and Kyung Hae Jung and Seock-Ah Im and T. -Y. Kim and Jee Hyun Kim and Yong Seog Park and Tae Won Kim},
  journal={American journal of clinical oncology},
  year={2014},
  volume={37 1},
  pages={19-23}
}
BACKGROUND Bevacizumab plus doublet chemotherapy has become one of the standard treatments for patients with metastatic colorectal cancer (mCRC). We have investigated the efficacy and safety of bevacizumab plus capecitabine and oxaliplatin as first-line chemotherapy for Korean patients with mCRC. METHODS Patients were treated with bevacizumab 7.5 mg/kg and oxaliplatin 130 mg/m on day 1 and capecitabine 2000 mg/m/d on days 1 to 14. After 9 cycles, patients were entered into the maintenance… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-6 of 6 extracted citations

Similar Papers

Loading similar papers…